[go: up one dir, main page]

MX2019007010A - Compuestos y composiciones para el tratamiento del cancer. - Google Patents

Compuestos y composiciones para el tratamiento del cancer.

Info

Publication number
MX2019007010A
MX2019007010A MX2019007010A MX2019007010A MX2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A MX 2019007010 A MX2019007010 A MX 2019007010A
Authority
MX
Mexico
Prior art keywords
formula
compounds
cancer
treatment
compositions
Prior art date
Application number
MX2019007010A
Other languages
English (en)
Other versions
MX381345B (es
Inventor
Zacharie Boulos
Gagnon Lyne
Grouix Brigitte
Laurin Pierre
Geerts Lillianne
Penney Christopher
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MX2019007010A publication Critical patent/MX2019007010A/es
Publication of MX381345B publication Critical patent/MX381345B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nuevos usos para compuestos de carboxilato de feniceltona y compuestos aromáticos sustituidos de Fórmula I, Fórmula 1.1, Fórmula 1.2, Fórmula 1A, Fórmula IB, Fórmula IC y Fórmula II y sus sales farmacéuticamente aceptables para el tratamiento del cáncer. Se describe el uso de una combinación de dos de estos compuestos y el uso de la combinación de uno de estos compuestos con un agente anticanceroso, tal como decarbazina, doxorrubicina, daunorrubicina, ciclofosfamida, busulfex, busulfán, vinblastina, vincristina, bleomicina, etopósido, topotecán, irinotecán, taxotere, taxol, 5-fluorouracilo, metotrexato, gemcitabina, cisplatino, carboplatino y clorambucilo.
MX2019007010A 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cancer. MX381345B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27
PCT/CA2011/001179 WO2012097427A1 (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2019007010A true MX2019007010A (es) 2019-09-06
MX381345B MX381345B (es) 2025-03-12

Family

ID=46515034

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004832A MX365807B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer.
MX2019007010A MX381345B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013004832A MX365807B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer.

Country Status (24)

Country Link
US (2) US9114118B2 (es)
EP (2) EP3443957B1 (es)
JP (2) JP6007186B2 (es)
KR (2) KR101943280B1 (es)
CN (2) CN105997967B (es)
AU (2) AU2011356583C1 (es)
BR (1) BR112013010507A2 (es)
CA (1) CA2816093C (es)
CL (1) CL2013001152A1 (es)
DK (2) DK3443957T3 (es)
EA (2) EA030038B1 (es)
ES (2) ES2703257T3 (es)
IL (2) IL225599A (es)
MX (2) MX365807B (es)
MY (2) MY184343A (es)
NZ (1) NZ610851A (es)
PH (2) PH12013500766B1 (es)
PL (2) PL3443957T3 (es)
PT (2) PT3443957T (es)
SG (2) SG189538A1 (es)
TR (1) TR201819987T4 (es)
TW (2) TWI620563B (es)
WO (1) WO2012097427A1 (es)
ZA (1) ZA201303035B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3443957T3 (da) * 2010-10-27 2020-12-21 Liminal Biosciences Ltd Forbindelser og sammensætninger til behandling af cancer
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
MY187511A (en) * 2014-10-10 2021-09-24 Prometic Pharma Smt Ltd Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
PL3203999T3 (pl) * 2014-10-10 2020-07-27 Liminal Biosciences Limited Podstawione związki aromatyczne i kompozycje farmaceutyczne do zapobiegania i leczenia osteoporozy
KR20170072352A (ko) * 2014-11-12 2017-06-26 프로메틱 파마 에스엠티 리미티드 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
PE20210041A1 (es) 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
CA3121830A1 (en) * 2018-12-05 2020-06-11 Liminal R&D Biosciences Inc. Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
ES2991100T3 (es) 2019-07-26 2024-12-02 Espervita Therapeutics Inc Acidos monocarboxílicos y dicarboxílicos de hidrocarburos de cadena larga funcionalizados útiles para la prevención o el tratamiento de enfermedades
CA3195137A1 (en) * 2020-10-06 2022-04-14 Lyne Gagnon Substituted aromatic compounds and pharmaceutical compositions thereof
CA3209453A1 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives therof, and their use for the prevention or treatment of disease
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途
AU2024239546A1 (en) * 2023-03-22 2025-10-02 Uti Limited Partnership Hydroxyphenyl propanoate compounds for tumour immunotherapy, compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
CA2506897A1 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
ATE530176T1 (de) 2006-09-01 2011-11-15 Piramal Life Sciences Ltd Verwendung von kaffeesäure und ihren derivaten gegen krebs
ES2657484T3 (es) * 2007-02-08 2018-03-05 Emisphere Technologies, Inc. Agentes de administración de ácido fenilalquilcarboxílico
PT2299998T (pt) 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
EP2231166B1 (en) * 2007-12-19 2013-03-20 ProMetic BioSciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
WO2010127440A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
KR20120090011A (ko) * 2009-05-04 2012-08-16 프로메틱 바이오사이언시즈 인코포레이티드 3-펜틸페닐아세트산의 염 및 이의 약학적 용도
DK3443957T3 (da) * 2010-10-27 2020-12-21 Liminal Biosciences Ltd Forbindelser og sammensætninger til behandling af cancer

Also Published As

Publication number Publication date
AU2016201556B2 (en) 2017-09-14
AU2011356583B2 (en) 2015-12-24
PT2632452T (pt) 2019-01-10
US9114118B2 (en) 2015-08-25
TWI620563B (zh) 2018-04-11
US20150313856A1 (en) 2015-11-05
SG189538A1 (en) 2013-06-28
EP2632452A4 (en) 2014-05-07
EP3443957B1 (en) 2020-11-25
US20130217645A1 (en) 2013-08-22
TR201819987T4 (tr) 2019-01-21
MX365807B (es) 2019-06-14
ZA201303035B (en) 2014-06-25
MX381345B (es) 2025-03-12
BR112013010507A2 (pt) 2016-08-02
MY162420A (en) 2017-06-15
WO2012097427A1 (en) 2012-07-26
MX2013004832A (es) 2013-05-22
EA201370103A1 (ru) 2013-12-30
IL225599A0 (en) 2013-06-27
CA2816093A1 (en) 2012-07-26
CN105997967A (zh) 2016-10-12
AU2016201556A1 (en) 2016-04-14
TW201717928A (zh) 2017-06-01
PH12013500766A1 (en) 2013-06-24
KR101943280B1 (ko) 2019-01-28
KR20130132448A (ko) 2013-12-04
JP6007186B2 (ja) 2016-10-12
US9439882B2 (en) 2016-09-13
JP2013544799A (ja) 2013-12-19
IL251083A0 (en) 2017-04-30
CN103347509A (zh) 2013-10-09
TW201305097A (zh) 2013-02-01
PT3443957T (pt) 2020-12-18
CN103347509B (zh) 2016-06-08
EA035494B1 (ru) 2020-06-25
AU2011356583A1 (en) 2013-05-09
JP2016188247A (ja) 2016-11-04
EA201791585A1 (ru) 2018-05-31
DK2632452T3 (en) 2019-01-21
JP6371344B2 (ja) 2018-08-08
CA2816093C (en) 2020-12-01
HK1189836A1 (zh) 2014-06-20
IL251083B (en) 2018-07-31
EP2632452A1 (en) 2013-09-04
ES2837599T3 (es) 2021-06-30
EA030038B1 (ru) 2018-06-29
SG10201807622WA (en) 2018-10-30
IL225599A (en) 2017-05-29
EP3443957A1 (en) 2019-02-20
ES2703257T3 (es) 2019-03-07
PH12016502324A1 (en) 2019-07-15
PL3443957T3 (pl) 2021-05-04
CN105997967B (zh) 2019-08-23
KR20180011332A (ko) 2018-01-31
PH12013500766B1 (en) 2017-09-29
AU2011356583C1 (en) 2016-03-17
MY184343A (en) 2021-04-01
DK3443957T3 (da) 2020-12-21
PH12016502324B1 (en) 2023-10-11
KR101821646B1 (ko) 2018-01-25
CL2013001152A1 (es) 2014-01-10
NZ610851A (en) 2015-05-29
TWI578983B (zh) 2017-04-21
PL2632452T3 (pl) 2019-03-29
EP2632452B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
MX2019007010A (es) Compuestos y composiciones para el tratamiento del cancer.
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
PH12017502141A1 (en) Compounds and their methods of use
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
MX2018006503A (es) Compuesto novedoso de bifenilo o una sal del mismo.
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CL2015003491A1 (es) Compuestos químicos.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
CO6480975A2 (es) Mimetico de smac
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX381967B (es) Compuestos de 2,3-dihidrobenzofuran-5-ilo como inhibidores de quinasas dyrk.
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CR20150456A (es) Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen
CR20160016A (es) Pirazolpiridinas sustituidas